ASX:NEUPharmaceuticals
Does Neuren Pharmaceuticals' (ASX:NEU) Pre-IND Delay Hint At Deeper Pipeline Timing Trade-Offs?
Earlier this month, Neuren Pharmaceuticals disclosed that the FDA’s pre-IND meeting for its NNZ-2591 program was pushed back by one month to late January 2026, citing an administrative delay that could modestly affect the development timeline for hypoxic ischemic encephalopathy and other rare neurological indications.
This seemingly short postponement is important because NNZ-2591 is Neuren’s second key asset, already granted orphan drug designation in the US and EU, and any shift in its...